EudraPharm
EudraPharm, or the European Union Drug Regulating Authorities Pharmaceutical Database, serves as the centralized database for medicinal products that have received authorization within the European Union. Its comprehensive collection incorporates critical information related to the Summary of Product Characteristics, patient or user package leaflets, and data exhibited on the medicinal labelling.
Overview[edit | edit source]
The primary objective of the EudraPharm database is to provide transparent and accessible data to the public. In order to ensure the information is both beneficial and easily understood by all users, the database is constructed in a manner that is both comprehensive and user-friendly.
Regulatory Framework[edit | edit source]
The establishment and functioning of EudraPharm are rooted in EU Regulation 726/2004. This regulation outlines the procedures and criteria for granting medicinal product licenses within the European Union, and it mandates the maintenance of an accessible database of authorized products.
Content and Scope[edit | edit source]
EudraPharm's focus is largely on products that have undergone the Centralised procedure for licensing. This means that for human medicines, EudraPharm primarily acts as a revamped interface, presenting information previously available via the EPARs (European Public Assessment Reports) section at the European Medicines Agency (EMEA).
Accessibility and Usage[edit | edit source]
EudraPharm is open to the general public, ensuring that individuals, healthcare professionals, researchers, and policymakers can readily access information about authorized medicinal products within the EU. Given its transparency and comprehensiveness, it plays an integral role in promoting informed decisions related to medicinal usage and policy formulation.
See Also[edit | edit source]
- European Union
- European Medicines Agency (EMEA)
- Medicinal product licensing
- European Medicines Agency
- EUDRANET
- EudraCT
- EudraGMP
- EudraVigilance
External links[edit | edit source]
- EudraPharm
- EUDRANET
- Projects of Common Interest for Administrations (EU)
- European Medicines Agency Implementation of the New EU Pharmaceutical Legislation
- EPAR section at European Medicines Agency
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD